AMP Increases Position in SGYP


Today AMP increased its hypothetical stake in SGYP by over 25%, in the AMP hypothetical model fund. At the current market cap of SGYP of about $1 billion, early positive reports on the launch of ​Trulance for chronic constipation, and the likely future approval of Trulance for irritable bowel syndrome with constipation, AMP feels that the current valuation is an attractive re-entry point.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon